Search Within

Jaclyn Frances Hechtman

  1. "Radiology, Department of"
Formats
  1. Journal Article (11)
  2. Meeting Abstract (7)
  3. Guidelines (1)
Groups
  1. Department of Medicine (19)
  2. Radiology, Department of (19)
  3. Solid Tumor Oncology Division (19)
  4. GSK Faculty (17)
  5. Gastrointestinal Oncology Service (16)
  6. Body Imaging Service (15)

More Groups

People
  1. Nikolaus Schultz (11)
  2. David Solit (9)
  3. Marinela Capanu (9)
  4. Yelena Janjigian (9)
  5. David Ilson (8)
  6. Geoffrey Ku (8)

More People

Years
  1. 2023 (1)
  2. 2022 (1)
  3. 2021 (1)
  4. 2020 (3)
  5. 2019 (10)
  6. 2018 (2)

More Years

Publications
  1. Journal of Clinical Oncology (5)
  2. JCO Precision Oncology (4)
  3. Cancer Discovery (2)
  4. Clinical Cancer Research (2)
  5. Annals of Oncology (1)
  6. Cancer Research (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (9)
  2. American Association for Cancer Research (5)
  3. Cell Press (1)
  4. Elsevier Inc. (1)
  5. Elsevier Science, Inc. (1)
  6. Nature Publishing Group (1)

More Publishers

Results (19)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Determinants of survival with combined HER2 and PD-1 blockade in metastatic esophagogastric cancer
    Journal Article

    Maron, S. B.; Chatila, W.; Walch, H.; Chou, J. F.; Ceglia, N.; Ptashkin, R.; Do, R. K. G.; Paroder, V.; Pandit-Taskar, N.; Lewis, J. S.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1
    Journal Article

    Su, W.; Mukherjee, R.; Yaeger, R.; Son, J.; Xu, J.; Na, N.; Timaul, N. M.; Hechtman, J.; Paroder, V.; Lin, M.; more...
    Molecular Cell (2022)

    Fulltext@MSK | Save
  • Early predictors of benefit to dual anti-PD1/HER2 inhibition: Biomarker analysis from phase 2 trial of pembrolizumab/trastuzumab in HER2-positive metastatic esophagogastric (mEG) cancer
    Meeting Abstract

    Maron, S. B.; Chatila, W. K.; Walch, H. S.; Ptashkin, R.; Sabwa, S.; Ling, L.; Nagy, R.; Simmons, M.; Do, R. K. G.; Paroder, V.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • ctDNA applications and integration in colorectal cancer: An NCI Colon and Rectal–Anal Task Forces whitepaper
    Guidelines

    Dasari, A.; Morris, V. K.; Allegra, C. J.; Atreya, C.; Benson, A. B. 3rd; Boland, P.; Chung, K.; Copur, M. S.; Corcoran, R. B.; Deming, D. A.; more...
    Nature Reviews Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis
    Meeting Abstract

    Maron, S. B.; Chatila, W. K.; Millang, B. M.; Sabwa, S.; Chou, J. F.; Ling, L.; Nagy, R.; Simmons, M.; Do, R. K. G.; Paroder, V.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: An open-label, single-arm, phase 2 trial
    Journal Article

    Janjigian, Y. Y.; Maron, S. B.; Chatila, W. K.; Millang, B.; Chavan, S. S.; Alterman, C.; Chou, J. F.; Segal, M. F.; Simmons, M. Z.; Momtaz, P.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
    Meeting Abstract

    Janjigian, Y. Y.; Maron, S.; Chou, J. F.; Gabler, A. R.; Simmons, M. Z.; Momtaz, P.; Shcherba, M.; Ku, G. Y.; Won, E.; Sanchez-Vega, F.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
    Meeting Abstract

    Janjigian, Y. Y.; Maron, S. B.; Chou, J. F.; Gabler, A.; Simmons, M.; Momtaz, P.; Sanchez-Vega, F.; Shcherba, M.; Ku, G. Y.; Won, E.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O-) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA)
    Meeting Abstract

    Janjigian, Y. Y.; Chou, J. F.; Simmons, M.; Momtaz, P.; Sanchez-Vega, F.; Shcherba, M.; Ku, G. Y.; Won, E.; Chong, C. R.; Gerdes, H.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • ARAF activates RAS by antagonizing its interaction with NF1
    Meeting Abstract

    Su, W.; Yaeger, R.; Na, N.; Hechtman, J.; Paroder, V.; Misale, S.; Han, S. W.; Abdel-Wahab, O. I.; McCormick, F.; Rosen, N.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save